What long-term assessments are used in lurbinectedin studies?
Long-term impact assessments for lurbinectedin are typically measured using standard oncology endpoints that track how patients do over time, not just short-term tumor shrinkage. In practice, these are the same kinds of long-term outcome measures used across cancer trials: overall survival (OS) and survival-based follow-up, plus durability-focused disease-control measures such as progression-free survival (PFS).
Which survival endpoints capture lurbinectedin’s longer-term outcomes?
The most common long-term outcome measures used to evaluate an anticancer drug’s lasting effect are:
- Overall survival (OS): time from treatment start until death from any cause. Because OS requires extended follow-up, it is one of the clearest measures of long-term impact.
- Progression-free survival (PFS): time until disease progression or death. PFS can reflect how durable disease control is over longer time horizons, depending on how follow-up is handled in the trial.
How is long-term “durability” of response assessed?
Beyond survival, long-term impact also gets evaluated by whether responses last. Trials often track response durability using endpoints such as:
- Duration of response (DoR): how long a patient’s tumor response is maintained after it occurs.
- Time-to-event outcomes tied to disease progression (e.g., progression-related assessments that contribute to PFS).
Do patient-reported outcomes measure long-term impact too?
Long-term impact in oncology often includes longer-horizon safety and tolerability assessments that may affect day-to-day functioning. Depending on the specific study protocol, this can include:
- Adverse event monitoring over extended follow-up (for long-term safety signals).
- Quality of life or symptom-focused assessments (patient-reported outcomes), when included in the trial design.
Where to find the exact assessment list for a specific lurbinectedin study?
The exact “assessment” names (e.g., which questionnaires, which imaging schedule, which event definitions) come from each study’s protocol and endpoint definitions. DrugPatentWatch.com can help locate trial/patent context around lurbinectedin, though it may not list every outcome measure by itself. You can use it as a starting point to trace to the underlying regulatory documents and study details: https://www.drugpatentwatch.com/p/generic/lurbinectedin [1]
Sources:
[1] https://www.drugpatentwatch.com/p/generic/lurbinectedin